Orthogon Therapeutics today announced the closing of a follow-on $11 million financing, bringing its total capital raised to ...

TG Therapeutics, Inc. (NASDAQ: TGTX), announced the completion of enrollment in a Phase 3 trial evaluating subcutaneous BRIUMVI (ublituximab-xiiy), the Company’s anti-CD20 monoclonal antibody, in ...

Progressive multifocal leukoencephalopathy (PML), caused by reactivation of JC virus, typically develops in individuals with profound immunosuppression, but may also occur in those with more subtle ...

OT gathers the latest in contact lens news at 100% Optical: from focusing on materials, to a new modality, and meeting the needs of presbyopes ...

Data from a poster presented at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Annual Congress held in Barcelona, Spain, from 24 th –26 th September 2025 The poster ...

Genentech's Fenebrutinib Confirms Its Potential as First and Only BTK Inhibitor for Relapsing and Primary Progressive MS in Third Positive Phase III Study (FENhance 1) -FENhance 1 met its primary ...

-FENhance 1 met its primary endpoint, showing investigational fenebrutinib significantly reduced relapses by 51% compared to teriflunomide in relapsing multiple sclerosis (RMS), consistent with ...

Progressive multifocal leukoencephalopathy (PML) is a rare and often fatal demyelinating disease of the central nervous system (CNS) caused by the reactivation of the JC polyomavirus (JCPyV). While ...

Progressive multifocal leukoencephalopathy (PML) is a rare but serious brain infection. It gradually destroys brain tissue and often leads to death within a few weeks. It is triggered by human ...

– Late-breaking Phase III FENtrepid results presented at ACTRIMS show investigational fenebrutinib met its primary endpoint of non-inferiority compared to the current standard of care, Ocrevus, in ...